News & events

Press releases

17 April 2019, Sophia Antipolis, France

Median Technologies adopts a new governance structure and dissociates the functions of Chairman of the Board of Directors and of Chief Executive Officer

Median Technologies, The Imaging Phenomics Company® (ALMDT) announces today that on April 10th, the Board of Directors decided to adopt a new governance structure for Median aiming at dissociating the functions of Chairman of the Board of Directors and Chief Executive officer. The Company’s new governance was effective immediately. As a result, on April 10th, 2019, Oran Muduroglu was appointed Chairman of the Board of Directors. Fredrik Brag will continue in his role as Chief Executive Officer of Median Technologies.

Read more
See all press releases

Conferences

May 31 - June 4, 2019 | McCormick Place, Chicago, IL, USA

ASCO 2019

Median will be exhibiting at ASCO 2019 from May 31 to June 4 in Chicago, IL.  Please stop by booth #6102 to learn more about our breakthrough imaging solutions and services for oncology clinical trials and our Imaging Phenomics platform iBiopsy®. Happy to see you there!

Visit conference website
See all conferences

In the press

iBiopsy® for Precision Medicine

Check out our paper published in the European Medical Journal on December 13, 2018 in order to educate the oncology specialists across Europe and the US as to the high-throughput artificial intelligence powered image-base phenotyping platform, iBiopsy® -> http://viewer.zmags.com/publication/647c38a3#/647c38a3/50

Abstract

A high-throughput artificial intelligence-powered image-based phenotyping platform, iBiopsy® (Median Technologies, Valbonne, France), which aims to improve precision medicine, is discussed in the presented review. The article introduces novel concepts, including high-throughput, fully automated imaging biomarker extraction; unsupervised predictive learning; large-scale content-based image-based similarity search; the use of large-scale clinical data registries; and cloud-based big data analytics to the problems of disease subtyping and treatment planning. Unlike electronic health record-based approaches, which lack the detailed radiological, pathological, genomic, and molecular data necessary for accurate prediction, iBiopsy® generates unique signatures as fingerprints of disease and tumor subtypes from target images. These signatures are then merged with any additional omics data and matched against a large-scale reference registry of deeply phenotyped patients. Initial applications targeted include hepatocellular carcinoma and other chronic liver diseases, such as nonalcoholic steatohepatitis. This new disruptive technology is expected to lead to the identification of appropriate therapies targeting specific molecular pathways involved in the detected phenotypes to bring personalised treatment to patients, taking into account individual biological variability, which is the principal aim of precision medicine.

See all in the press

Blog

See all blog entries

Cookies help us deliver our services. By using our services, you agree to our use of cookies.